Crescent Biopharma (CBIO)
Develops antibody medicines for solid tumors through bispecific and ADC programs.
Something off on this page? Send us feedback.
Develops investigational antibody therapies for solid tumors, centered on CR-001, a PD-1 × VEGF bispecific, and an antibody-drug conjugate portfolio. Its public listing followed a reverse recapitalization with GlycoMimetics, while progress depends on clinical execution and a China program with Kelun-Biotech.
Advances CR-001, an investigational tetravalent PD-1 × VEGF bispecific antibody, alongside antibody-drug conjugate programs for solid tumors. The portfolio draws on candidates licensed from Paragon Therapeutics for treating solid tumors and uses multiple modalities and established targets.
Clinical development includes the global Phase 1/2 ASCEND trial of CR-001 across multiple solid-tumor types and a Phase 1/2 CR-003 trial in China. The company expects CR-002 to enter the clinic.
Nasdaq trading began after a reverse recapitalization with GlycoMimetics. Program progress is tied to clinical execution and the China trial involving Kelun-Biotech.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral | ||
| Feb 26, 2026 | Stifel Nicolaus | Target | $32 | $29 | ||
| Jan 28, 2026 | Piper Sandler | Target | $35 | |||
| Jan 21, 2026 | Guggenheim | Target | $35 | |||
| Dec 4, 2025 | Stifel Nicolaus | Target | $32 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $171.6M · Total debt $1.4M · Total assets $182.8M · Shareholders' equity $163.3M
- Revenue
- $0
- Operating income
- −$26.4M
- Net income
- −$22.7M
No dividends on record.
| Institutions60 holders · as of Mar 31, 2026 | 67.61% | 25.11M shares | |
| Insiders8 holders · as of Jun 23, 2026 | 1.56% | 580.4K shares | |
| Strategic holders1 holder · as of Jun 10, 2019 | 0.13% | 47.7K shares | |
| Otherremainder | 30.70% | 11.40M shares |
37.14M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
FMR LLCInstitution | 11.13% | 4.13M | 13Fas of Mar 31, 2026 |
BVF Inc/ILInstitution | 7.40% | 2.75M | 13Fas of Mar 31, 2026 |
Fairmount Funds Management LLCInstitution | 7.40% | 2.75M | 13Fas of Mar 31, 2026 |
VR Adviser, LLCInstitution | 5.74% | 2.13M | 13Fas of Mar 31, 2026 |
FCPM Iii Services B.V.Institution | 4.52% | 1.68M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 16, 2026 | Fairmount Funds Management LLC | director, 10 percent owner: | +1,379,347 | $8.97 |
| Jun 22, 2026 | Joshua T. Brumm | director, officer: Chief Executive Officer | −42,305 | $17.99 |
| Jun 22, 2026 | Jonathan McNeill | officer: President and COO | −20,549 | $17.99 |
| Jun 22, 2026 | Ellie Eunkyung Im | officer: Chief Medical Officer | −1,219 | $17.99 |
| Jun 22, 2026 | Barbara Harlin Bispham | officer: See Remarks | −1,218 | $17.99 |
- Summit Therapeutics
Licensed PD-1 × VEGF bispecific for global NSCLC development
- BioNTech (ADR)
PD-L1 × VEGF bispecific in global NSCLC and solid-tumor trials
- Merck
PD-1 × VEGF bispecific and marketed PD-1 oncology backbone
- Pfizer
PD-1 × VEGF bispecific and integrin β6 ADC programs in solid tumors
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Crescent Biopharma | $18.27 | −1.30% | $688.6M | — | — | 58.0 | — |
| Summit Therapeutics | $15.31 | +4.86% | $11.65B | — | — | — | — |
| BioNTech (ADR) | $104.00 | +0.22% | $26.08B | — | — | 8.5 | −60.7% |
| Merck | $151.72 | +0.05% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Pfizer | $28.98 | −0.17% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Median | 79.8 | 14.0 | 5.6 | +2.6% |